25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Lineage Cell Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Lineage Cell Therapeutics Inc together

I guess you are interested in Lineage Cell Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Lineage Cell Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Lineage Cell Therapeutics Inc

I send you an email if I find something interesting about Lineage Cell Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Lineage Cell Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Lineage Cell Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
17.5%

What is your share worth?

Current worth
$0.29
Expected worth in 1 year
$0.29
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-0.01
Return On Investment
-1.5%

For what price can you sell your share?

Current Price per Share
$0.56
Expected price per share
$0 - $0.7665
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Lineage Cell Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$0.56
Intrinsic Value Per Share
$-1.16 - $-0.44
Total Value Per Share
$-0.87 - $-0.15

2.2. Growth of Lineage Cell Therapeutics Inc (5 min.)




Is Lineage Cell Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$64.7m$69.7m-$3.5m-5.4%

How much money is Lineage Cell Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$5m-$5.8m$806k16.0%
Net Profit Margin-292.8%-315.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Lineage Cell Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#418 / 943

Most Revenue
#430 / 943

Most Profit
#432 / 943

Most Efficient
#558 / 943
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Lineage Cell Therapeutics Inc?

Welcome investor! Lineage Cell Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Lineage Cell Therapeutics Inc.

First you should know what it really means to hold a share of Lineage Cell Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Lineage Cell Therapeutics Inc is $0.558. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lineage Cell Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lineage Cell Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.29. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lineage Cell Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.01-2.5%-0.02-4.1%-0.03-4.7%-0.03-5.3%-0.03-4.7%
Usd Book Value Change Per Share-0.01-1.7%0.00-0.4%-0.01-2.2%-0.01-2.1%0.000.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.1%0.011.4%
Usd Total Gains Per Share-0.01-1.7%0.00-0.4%-0.01-2.2%-0.01-2.0%0.011.9%
Usd Price Per Share0.91-1.12-1.32-1.47-2.00-
Price to Earnings Ratio-16.44--12.76--13.26--13.42--10.38-
Price-to-Total Gains Ratio-95.89--41.18--19.78--29.92--14.90-
Price to Book Ratio3.08-3.71-4.16-3.74-4.81-
Price-to-Total Gains Ratio-95.89--41.18--19.78--29.92--14.90-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.558
Number of shares1792
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.00-0.01
Usd Total Gains Per Share0.00-0.01
Gains per Quarter (1792 shares)-3.79-19.76
Gains per Year (1792 shares)-15.17-79.02
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-15-253-82-89
20-30-407-165-168
30-46-5510-247-247
40-61-7014-330-326
50-76-8517-412-405
60-91-10021-495-484
70-106-11524-577-563
80-121-13028-660-642
90-137-14531-742-721
100-152-16035-825-800

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%7.033.00.017.5%9.0118.00.07.1%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%5.015.00.025.0%15.025.00.037.5%37.085.05.029.1%
Dividend per Share0.00.04.00.0%2.00.010.016.7%4.00.016.020.0%7.00.033.017.5%7.00.0120.05.5%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%5.015.00.025.0%16.024.00.040.0%38.084.05.029.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Lineage Cell Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.009-0.002-78%-0.012+31%-0.012+22%0.003-422%
Book Value Per Share--0.2940.300-2%0.316-7%0.394-25%0.465-37%
Current Ratio--2.4812.4930%2.951-16%4.742-48%4.619-46%
Debt To Asset Ratio--0.3290.353-7%0.386-15%0.276+19%0.197+67%
Debt To Equity Ratio--0.4910.537-9%0.617-20%0.425+15%0.382+28%
Dividend Per Share----0%0.000-100%0.000-100%0.008-100%
Enterprise Value--200453604.800247984150.400-19%293873290.000-32%339316545.840-41%454593223.215-56%
Eps---0.014-0.023+66%-0.026+90%-0.030+116%-0.026+89%
Ev To Ebitda Ratio---13.548-12.277-9%-12.704-6%-13.925+3%-10.295-24%
Ev To Sales Ratio--13.26134.658-62%36.615-64%153.690-91%243.504-95%
Free Cash Flow Per Share---0.026-0.026+0%-0.036+38%-0.021-17%-0.033+28%
Free Cash Flow To Equity Per Share---0.026-0.010-62%-0.028+9%-0.001-95%-0.001-95%
Gross Profit Margin--1.0001.019-2%1.0000%1.0040%1.0020%
Intrinsic Value_10Y_max---0.441--------
Intrinsic Value_10Y_min---1.160--------
Intrinsic Value_1Y_max---0.073--------
Intrinsic Value_1Y_min---0.130--------
Intrinsic Value_3Y_max---0.197--------
Intrinsic Value_3Y_min---0.382--------
Intrinsic Value_5Y_max---0.295--------
Intrinsic Value_5Y_min---0.620--------
Market Cap122992128.000-62%199542604.800246458150.400-19%289847040.000-31%324422595.840-38%439961907.840-55%
Net Profit Margin---0.803-2.928+265%-3.154+293%-10.595+1220%-9.439+1076%
Operating Margin---1.016-3.013+197%-3.274+222%-15.180+1394%-32.749+3123%
Operating Ratio--2.0164.211-52%4.297-53%14.770-86%23.862-92%
Pb Ratio1.898-62%3.0803.709-17%4.160-26%3.744-18%4.808-36%
Pe Ratio-10.134+38%-16.442-12.757-22%-13.264-19%-13.425-18%-10.381-37%
Price Per Share0.558-62%0.9051.118-19%1.315-31%1.472-38%1.996-55%
Price To Free Cash Flow Ratio-5.395+38%-8.753-10.777+23%-9.871+13%-12.751+46%-13.580+55%
Price To Total Gains Ratio-59.102+38%-95.888-41.185-57%-19.780-79%-29.915-69%-14.898-84%
Quick Ratio--2.7462.618+5%4.239-35%5.531-50%5.102-46%
Return On Assets---0.031-0.049+55%-0.052+64%-0.054+71%-0.064+104%
Return On Equity---0.047-0.074+58%-0.082+76%-0.080+71%-0.163+248%
Total Gains Per Share---0.009-0.002-78%-0.012+30%-0.011+17%0.011-187%
Usd Book Value--64794000.00066170500.000-2%69717250.000-7%86874400.000-25%102477588.725-37%
Usd Book Value Change Per Share---0.009-0.002-78%-0.012+31%-0.012+22%0.003-422%
Usd Book Value Per Share--0.2940.300-2%0.316-7%0.394-25%0.465-37%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.008-100%
Usd Enterprise Value--200453604.800247984150.400-19%293873290.000-32%339316545.840-41%454593223.215-56%
Usd Eps---0.014-0.023+66%-0.026+90%-0.030+116%-0.026+89%
Usd Free Cash Flow---5699000.000-5714000.000+0%-7854250.000+38%-4730100.000-17%-7282429.250+28%
Usd Free Cash Flow Per Share---0.026-0.026+0%-0.036+38%-0.021-17%-0.033+28%
Usd Free Cash Flow To Equity Per Share---0.026-0.010-62%-0.028+9%-0.001-95%-0.001-95%
Usd Market Cap122992128.000-62%199542604.800246458150.400-19%289847040.000-31%324422595.840-38%439961907.840-55%
Usd Price Per Share0.558-62%0.9051.118-19%1.315-31%1.472-38%1.996-55%
Usd Profit---3034000.000-5027750.000+66%-5833750.000+92%-6798700.000+124%-5827072.625+92%
Usd Revenue--3779000.0002179750.000+73%2193000.000+72%1789000.000+111%1121270.475+237%
Usd Total Gains Per Share---0.009-0.002-78%-0.012+30%-0.011+17%0.011-187%
 EOD+3 -5MRQTTM+18 -20YOY+23 -165Y+17 -2310Y+15 -25

3.3 Fundamental Score

Let's check the fundamental score of Lineage Cell Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-10.134
Price to Book Ratio (EOD)Between0-11.898
Net Profit Margin (MRQ)Greater than0-0.803
Operating Margin (MRQ)Greater than0-1.016
Quick Ratio (MRQ)Greater than12.746
Current Ratio (MRQ)Greater than12.481
Debt to Asset Ratio (MRQ)Less than10.329
Debt to Equity Ratio (MRQ)Less than10.491
Return on Equity (MRQ)Greater than0.15-0.047
Return on Assets (MRQ)Greater than0.05-0.031
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Lineage Cell Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.607
Ma 20Greater thanMa 500.552
Ma 50Greater thanMa 1000.736
Ma 100Greater thanMa 2000.813
OpenGreater thanClose0.520
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Fundamental data was last updated by Penke on 2024-12-16 23:13:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Lineage Cell Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Lineage Cell Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -80.3% means that $-0.80 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lineage Cell Therapeutics Inc:

  • The MRQ is -80.3%. The company is making a huge loss. -2
  • The TTM is -292.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-80.3%TTM-292.8%+212.5%
TTM-292.8%YOY-315.4%+22.6%
TTM-292.8%5Y-1,059.5%+766.7%
5Y-1,059.5%10Y-943.9%-115.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-80.3%-109.0%+28.7%
TTM-292.8%-220.8%-72.0%
YOY-315.4%-207.5%-107.9%
5Y-1,059.5%-350.0%-709.5%
10Y-943.9%-473.2%-470.7%
4.3.1.2. Return on Assets

Shows how efficient Lineage Cell Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Lineage Cell Therapeutics Inc to the Biotechnology industry mean.
  • -3.1% Return on Assets means that Lineage Cell Therapeutics Inc generated $-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lineage Cell Therapeutics Inc:

  • The MRQ is -3.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -4.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.1%TTM-4.9%+1.7%
TTM-4.9%YOY-5.2%+0.3%
TTM-4.9%5Y-5.4%+0.5%
5Y-5.4%10Y-6.4%+1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.1%-11.6%+8.5%
TTM-4.9%-11.9%+7.0%
YOY-5.2%-11.2%+6.0%
5Y-5.4%-12.6%+7.2%
10Y-6.4%-14.2%+7.8%
4.3.1.3. Return on Equity

Shows how efficient Lineage Cell Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Lineage Cell Therapeutics Inc to the Biotechnology industry mean.
  • -4.7% Return on Equity means Lineage Cell Therapeutics Inc generated $-0.05 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lineage Cell Therapeutics Inc:

  • The MRQ is -4.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.7%TTM-7.4%+2.7%
TTM-7.4%YOY-8.2%+0.8%
TTM-7.4%5Y-8.0%+0.6%
5Y-8.0%10Y-16.3%+8.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.7%-14.3%+9.6%
TTM-7.4%-15.9%+8.5%
YOY-8.2%-14.7%+6.5%
5Y-8.0%-18.5%+10.5%
10Y-16.3%-19.2%+2.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Lineage Cell Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Lineage Cell Therapeutics Inc is operating .

  • Measures how much profit Lineage Cell Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Lineage Cell Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -101.6% means the company generated $-1.02  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lineage Cell Therapeutics Inc:

  • The MRQ is -101.6%. The company is operating very inefficient. -2
  • The TTM is -301.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-101.6%TTM-301.3%+199.7%
TTM-301.3%YOY-327.4%+26.0%
TTM-301.3%5Y-1,518.0%+1,216.7%
5Y-1,518.0%10Y-3,274.9%+1,756.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-101.6%-208.0%+106.4%
TTM-301.3%-316.8%+15.5%
YOY-327.4%-216.9%-110.5%
5Y-1,518.0%-379.8%-1,138.2%
10Y-3,274.9%-480.9%-2,794.0%
4.3.2.2. Operating Ratio

Measures how efficient Lineage Cell Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.02 means that the operating costs are $2.02 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Lineage Cell Therapeutics Inc:

  • The MRQ is 2.016. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.211. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.016TTM4.211-2.195
TTM4.211YOY4.297-0.087
TTM4.2115Y14.770-10.559
5Y14.77010Y23.862-9.092
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0162.284-0.268
TTM4.2113.244+0.967
YOY4.2973.262+1.035
5Y14.7704.764+10.006
10Y23.8626.437+17.425
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Lineage Cell Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Lineage Cell Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.48 means the company has $2.48 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Lineage Cell Therapeutics Inc:

  • The MRQ is 2.481. The company is able to pay all its short-term debts. +1
  • The TTM is 2.493. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.481TTM2.493-0.012
TTM2.493YOY2.951-0.458
TTM2.4935Y4.742-2.249
5Y4.74210Y4.619+0.123
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4813.569-1.088
TTM2.4933.865-1.372
YOY2.9514.644-1.693
5Y4.7425.968-1.226
10Y4.6196.209-1.590
4.4.3.2. Quick Ratio

Measures if Lineage Cell Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Lineage Cell Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 2.75 means the company can pay off $2.75 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lineage Cell Therapeutics Inc:

  • The MRQ is 2.746. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.618. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.746TTM2.618+0.128
TTM2.618YOY4.239-1.620
TTM2.6185Y5.531-2.912
5Y5.53110Y5.102+0.429
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7463.086-0.340
TTM2.6183.384-0.766
YOY4.2394.304-0.065
5Y5.5315.954-0.423
10Y5.1026.436-1.334
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Lineage Cell Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Lineage Cell Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Lineage Cell Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.33 means that Lineage Cell Therapeutics Inc assets are financed with 32.9% credit (debt) and the remaining percentage (100% - 32.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Lineage Cell Therapeutics Inc:

  • The MRQ is 0.329. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.353. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.329TTM0.353-0.023
TTM0.353YOY0.386-0.033
TTM0.3535Y0.276+0.077
5Y0.27610Y0.197+0.079
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3290.346-0.017
TTM0.3530.346+0.007
YOY0.3860.311+0.075
5Y0.2760.365-0.089
10Y0.1970.383-0.186
4.5.4.2. Debt to Equity Ratio

Measures if Lineage Cell Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Lineage Cell Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 49.1% means that company has $0.49 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lineage Cell Therapeutics Inc:

  • The MRQ is 0.491. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.537. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.491TTM0.537-0.047
TTM0.537YOY0.617-0.080
TTM0.5375Y0.425+0.112
5Y0.42510Y0.382+0.043
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4910.393+0.098
TTM0.5370.432+0.105
YOY0.6170.387+0.230
5Y0.4250.453-0.028
10Y0.3820.498-0.116
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Lineage Cell Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Lineage Cell Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -16.44 means the investor is paying $-16.44 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lineage Cell Therapeutics Inc:

  • The EOD is -10.134. Based on the earnings, the company is expensive. -2
  • The MRQ is -16.442. Based on the earnings, the company is expensive. -2
  • The TTM is -12.757. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.134MRQ-16.442+6.308
MRQ-16.442TTM-12.757-3.685
TTM-12.757YOY-13.264+0.507
TTM-12.7575Y-13.425+0.668
5Y-13.42510Y-10.381-3.044
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.134-2.088-8.046
MRQ-16.442-2.565-13.877
TTM-12.757-3.166-9.591
YOY-13.264-3.244-10.020
5Y-13.425-6.006-7.419
10Y-10.381-6.718-3.663
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lineage Cell Therapeutics Inc:

  • The EOD is -5.395. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.753. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.777. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.395MRQ-8.753+3.358
MRQ-8.753TTM-10.777+2.024
TTM-10.777YOY-9.871-0.907
TTM-10.7775Y-12.751+1.974
5Y-12.75110Y-13.580+0.829
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.395-2.720-2.675
MRQ-8.753-3.295-5.458
TTM-10.777-3.674-7.103
YOY-9.871-4.477-5.394
5Y-12.751-8.054-4.697
10Y-13.580-9.225-4.355
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Lineage Cell Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.08 means the investor is paying $3.08 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Lineage Cell Therapeutics Inc:

  • The EOD is 1.898. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.080. Based on the equity, the company is fair priced.
  • The TTM is 3.709. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD1.898MRQ3.080-1.181
MRQ3.080TTM3.709-0.629
TTM3.709YOY4.160-0.451
TTM3.7095Y3.744-0.036
5Y3.74410Y4.808-1.063
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.8981.866+0.032
MRQ3.0802.055+1.025
TTM3.7092.392+1.317
YOY4.1602.453+1.707
5Y3.7443.716+0.028
10Y4.8084.373+0.435
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Lineage Cell Therapeutics Inc.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets96,594
Total Liabilities31,800
Total Stockholder Equity64,794
 As reported
Total Liabilities 31,800
Total Stockholder Equity+ 64,794
Total Assets = 96,594

Assets

Total Assets96,594
Total Current Assets34,401
Long-term Assets62,193
Total Current Assets
Cash And Cash Equivalents 27,750
Short-term Investments 4,961
Net Receivables 405
Other Current Assets 1,285
Total Current Assets  (as reported)34,401
Total Current Assets  (calculated)34,401
+/-0
Long-term Assets
Property Plant Equipment 4,375
Goodwill 10,672
Intangible Assets 46,540
Long-term Assets Other 606
Long-term Assets  (as reported)62,193
Long-term Assets  (calculated)62,193
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities13,864
Long-term Liabilities17,936
Total Stockholder Equity64,794
Total Current Liabilities
Short-term Debt 1,137
Accounts payable 1,599
Other Current Liabilities 2,878
Total Current Liabilities  (as reported)13,864
Total Current Liabilities  (calculated)5,614
+/- 8,250
Long-term Liabilities
Capital Lease Obligations 2,750
Long-term Liabilities  (as reported)17,936
Long-term Liabilities  (calculated)2,750
+/- 15,186
Total Stockholder Equity
Common Stock469,268
Retained Earnings -400,192
Accumulated Other Comprehensive Income -2,890
Other Stockholders Equity -1,392
Total Stockholder Equity (as reported)64,794
Total Stockholder Equity (calculated)64,794
+/-0
Other
Capital Stock469,268
Cash and Short Term Investments 32,711
Common Stock Shares Outstanding 188,835
Current Deferred Revenue8,250
Liabilities and Stockholders Equity 96,594
Net Debt -25,000
Net Invested Capital 66,186
Net Working Capital 20,537
Property Plant and Equipment Gross 8,568
Short Long Term Debt Total 2,750



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-311996-12-311996-09-301996-06-301996-03-311995-12-311995-09-301995-06-301995-03-311994-12-311994-09-301994-06-301994-03-311993-12-311993-09-301993-06-301993-03-311992-12-311992-09-301992-06-301992-03-31
> Total Assets 
5,200
4,800
4,500
4,100
3,900
3,500
3,500
2,800
6,400
5,900
5,500
4,700
4,100
3,600
3,000
0
0
3,000
2,500
2,300
7,700
8,300
7,700
6,700
5,600
4,600
3,800
2,800
9,300
8,400
7,000
5,679
4,051
2,809
2,314
1,677
890
660
2,384
1,941
1,941
730
1,963
1,496
1,420
807
1,300
1,072
2,281
2,160
1,636
1,522
833
729
569
1,959
1,959
1,141
843
651
651
201
62
175
175
609
1,026
1,035
1,696
5,784
9,266
13,433
12,701
34,147
41,293
53,273
56,890
53,458
50,876
45,830
38,978
38,381
32,870
29,749
35,297
39,894
30,854
57,730
57,950
65,985
55,655
74,901
69,703
79,610
76,859
94,660
80,114
104,327
147,574
142,572
205,216
193,353
221,867
173,241
110,395
112,251
176,077
101,660
183,715
151,691
132,978
125,478
118,882
112,080
103,090
107,949
127,928
134,754
131,212
174,545
144,520
135,922
131,148
123,664
113,205
111,688
106,153
101,019
108,483
102,802
96,594
96,594102,802108,483101,019106,153111,688113,205123,664131,148135,922144,520174,545131,212134,754127,928107,949103,090112,080118,882125,478132,978151,691183,715101,660176,077112,251110,395173,241221,867193,353205,216142,572147,574104,32780,11494,66076,85979,61069,70374,90155,65565,98557,95057,73030,85439,89435,29729,74932,87038,38138,97845,83050,87653,45856,89053,27341,29334,14712,70113,4339,2665,7841,6961,0351,026609175175622016516518431,1411,9591,9595697298331,5221,6362,1602,2811,0721,3008071,4201,4961,9637301,9411,9412,3846608901,6772,3142,8094,0515,6797,0008,4009,3002,8003,8004,6005,6006,7007,7008,3007,7002,3002,5003,000003,0003,6004,1004,7005,5005,9006,4002,8003,5003,5003,9004,1004,5004,8005,200
   > Total Current Assets 
5,200
4,800
4,400
4,100
3,800
3,500
3,500
2,700
6,400
5,800
5,400
4,500
4,000
3,500
2,900
0
0
2,900
2,400
2,200
7,600
8,200
7,500
6,600
5,400
4,300
3,500
2,600
9,100
8,100
6,700
5,400
3,783
2,538
2,058
1,441
672
455
2,189
1,762
1,762
584
1,833
1,382
1,321
720
1,220
1,007
2,228
2,118
1,601
1,493
823
700
541
1,932
1,932
1,110
813
619
619
170
33
142
142
327
94
109
650
4,739
8,195
12,366
11,398
18,986
26,708
35,573
32,615
29,420
28,555
24,955
18,645
14,606
9,749
7,179
12,967
18,132
8,679
7,950
9,247
18,646
9,939
32,405
28,544
37,004
34,365
47,237
32,907
31,047
35,152
25,649
29,257
25,525
23,225
42,623
36,126
34,495
36,906
36,358
30,656
20,459
61,585
57,519
52,284
46,200
39,736
43,999
64,622
71,577
68,344
111,549
81,872
74,026
68,509
60,000
49,655
48,491
43,481
38,441
45,716
40,390
34,401
34,40140,39045,71638,44143,48148,49149,65560,00068,50974,02681,872111,54968,34471,57764,62243,99939,73646,20052,28457,51961,58520,45930,65636,35836,90634,49536,12642,62323,22525,52529,25725,64935,15231,04732,90747,23734,36537,00428,54432,4059,93918,6469,2477,9508,67918,13212,9677,1799,74914,60618,64524,95528,55529,42032,61535,57326,70818,98611,39812,3668,1954,73965010994327142142331706196198131,1101,9321,9325417008231,4931,6012,1182,2281,0071,2207201,3211,3821,8335841,7621,7622,1894556721,4412,0582,5383,7835,4006,7008,1009,1002,6003,5004,3005,4006,6007,5008,2007,6002,2002,4002,900002,9003,5004,0004,5005,4005,8006,4002,7003,5003,5003,8004,1004,4004,8005,200
       Cash And Cash Equivalents 
5,100
4,800
4,400
4,100
3,800
1,500
1,100
2,700
1,300
700
200
1,500
900
3,400
2,900
0
0
2,400
2,000
1,800
7,300
7,800
7,400
6,300
5,100
4,100
3,300
2,400
8,600
7,200
6,600
5,293
3,687
2,427
2,021
1,318
322
193
1,937
1,653
1,653
501
1,829
1,284
724
650
1,182
717
2,120
1,751
1,569
1,371
712
589
176
1,834
1,834
999
756
561
561
127
14
10
10
172
52
12
541
4,693
7,943
12,189
11,173
18,056
25,422
33,325
30,137
27,382
26,230
22,212
16,488
12,660
7,830
4,350
9,896
14,306
6,717
5,495
6,638
15,722
7,416
29,487
25,830
31,465
29,378
42,229
27,132
27,702
30,451
22,088
23,816
14,550
16,662
36,838
29,827
27,207
19,467
23,587
18,011
8,210
14,366
9,497
9,832
12,676
32,565
32,585
56,210
62,001
60,809
55,742
78,062
70,857
24,752
11,355
15,451
33,886
31,474
35,442
43,576
29,622
27,750
27,75029,62243,57635,44231,47433,88615,45111,35524,75270,85778,06255,74260,80962,00156,21032,58532,56512,6769,8329,49714,3668,21018,01123,58719,46727,20729,82736,83816,66214,55023,81622,08830,45127,70227,13242,22929,37831,46525,83029,4877,41615,7226,6385,4956,71714,3069,8964,3507,83012,66016,48822,21226,23027,38230,13733,32525,42218,05611,17312,1897,9434,69354112521721010141275615617569991,8341,8341765897121,3711,5691,7512,1207171,1826507241,2841,8295011,6531,6531,9371933221,3182,0212,4273,6875,2936,6007,2008,6002,4003,3004,1005,1006,3007,4007,8007,3001,8002,0002,400002,9003,4009001,5002007001,3002,7001,1001,5003,8004,1004,4004,8005,100
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
753
829
619
903
627
915
1,220
1,511
1,337
1,552
1,948
1,972
7,154
9,085
8,477
21,318
21,219
15,933
7,575
5,481
8,977
6,154
6,745
4,295
2,616
1,882
1,173
41,603
46,520
31,363
12,039
9,858
50
45
8,874
4,961
4,9618,87445509,85812,03931,36346,52041,6031,1731,8822,6164,2956,7456,1548,9775,4817,57515,93321,21921,3188,4779,0857,1541,9721,9481,5521,3371,5111,22091562790361982975300000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
300
900
0
0
0
0
0
0
0
0
0
0
0
0
0
0
511
3
0
0
0
301
6
0
0
0
256
0
506
7
8
0
4
6
5
0
10
4
5
0
0
0
135
0
0
0
253
0
0
0
0
0
0
0
0
0
0
0
0
0
818
1,191
1,014
1,420
1,143
3,750
2,975
1,645
2,068
939
1,719
1,157
3,013
3,066
3,698
3,046
2,998
3,769
13,706
3,719
1,402
1,671
23,559
23,940
24,294
24,572
276
4
109
326
79
50,840
515
707
434
297
203
443
432
745
77
235
405
4052357774543244320329743470751550,84079326109427624,57224,29423,94023,5591,6711,4023,71913,7063,7692,9983,0463,6983,0663,0131,1571,7199392,0681,6452,9753,7501,1431,4201,0141,191818000000000000025300013500054100564087506025600063010003511000000000000009003000000000000000000000000000000
       Other Current Assets 
100
0
0
0
0
2,000
2,400
0
5,100
5,100
5,200
3,000
3,100
100
0
0
0
300
200
200
100
300
0
300
300
200
200
0
200
0
100
107
96
111
38
123
251
262
252
0
0
83
4
98
87
67
38
290
108
65
27
122
112
112
109
0
98
104
49
0
58
37
14
0
132
151
37
97
109
46
118
139
169
881
984
2,202
2,407
1,981
2,264
2,692
2,102
1,891
1,861
2,774
3,018
3,761
1,901
2,276
1,554
1,476
1,255
1,232
1,272
1,492
1,752
2,609
2,878
1,787
2,079
1,777
1,513
1,589
1,354
1,402
1,749
1,571
1,761
1,898
2,158
2,101
2,342
2,863
2,225
1,377
1,414
2,433
2,149
2,505
3,161
2,351
1,413
1,289
1,720
1,828
2,638
2,123
1,717
2,204
2,018
1,659
1,285
1,2851,6592,0182,2041,7172,1232,6381,8281,7201,2891,4132,3513,1612,5052,1492,4331,4141,3772,2252,8632,3422,1012,1581,8981,7611,5711,7491,4021,3541,5891,5131,7772,0791,7872,8782,6091,7521,4921,2721,2321,2551,4761,5542,2761,9013,7613,0182,7741,8611,8912,1022,6922,2641,9812,4072,20298488116913911846109973715113201437580491049801091121121222765108290386787984830025226225112338111961071000200020020030030003001002002003000001003,1003,0005,2005,1005,10002,4002,0000000100
   > Long-term Assets 
0
0
100
0
100
100
100
100
100
100
100
200
100
100
100
0
0
100
100
100
100
100
200
100
200
300
300
200
200
300
300
279
268
271
256
236
219
206
195
179
179
146
130
114
99
87
80
64
53
43
34
29
10
29
28
0
27
30
30
0
32
30
29
0
33
282
932
927
1,046
1,045
1,071
1,067
1,302
15,161
14,585
17,700
24,275
24,038
22,321
20,874
20,333
23,775
23,122
22,569
22,330
21,762
22,174
49,780
48,703
47,339
45,715
42,496
41,159
42,606
42,494
47,423
47,207
73,280
112,422
116,923
175,959
167,828
198,642
130,618
74,269
77,756
139,171
65,302
153,059
131,232
71,393
67,959
66,598
65,880
63,354
63,950
63,306
63,177
62,868
62,996
62,648
61,896
62,639
63,664
63,550
63,197
62,672
62,578
62,767
62,412
62,193
62,19362,41262,76762,57862,67263,19763,55063,66462,63961,89662,64862,99662,86863,17763,30663,95063,35465,88066,59867,95971,393131,232153,05965,302139,17177,75674,269130,618198,642167,828175,959116,923112,42273,28047,20747,42342,49442,60641,15942,49645,71547,33948,70349,78022,17421,76222,33022,56923,12223,77520,33320,87422,32124,03824,27517,70014,58515,1611,3021,0671,0711,0451,04692793228233029303203030270282910293443536480879911413014617917919520621923625627126827930030020020030030020010020010010010010010000100100100200100100100100100100100010000
       Property Plant Equipment 
0
0
0
0
100
100
100
100
100
100
100
100
100
100
100
0
0
100
100
100
100
100
100
100
200
200
200
200
200
200
200
269
258
261
246
227
209
196
185
168
168
134
119
103
88
75
64
48
37
27
18
13
10
8
7
6
6
1
7
11
11
9
9
12
12
11
111
106
101
98
114
131
155
339
353
711
1,029
1,218
1,291
1,348
1,385
1,299
1,251
1,349
1,742
1,841
2,906
2,998
2,959
2,983
2,758
2,858
2,865
5,652
6,781
7,539
8,932
4,062
4,726
5,529
4,992
5,240
5,423
5,533
5,366
5,014
5,117
5,835
8,918
8,720
8,844
8,175
7,539
7,142
4,849
5,630
5,114
5,008
4,728
4,872
4,548
3,869
4,652
5,673
5,584
5,310
4,854
4,767
4,959
4,602
4,375
4,3754,6024,9594,7674,8545,3105,5845,6734,6523,8694,5484,8724,7285,0085,1145,6304,8497,1427,5398,1758,8448,7208,9185,8355,1175,0145,3665,5335,4235,2404,9925,5294,7264,0628,9327,5396,7815,6522,8652,8582,7582,9832,9592,9982,9061,8411,7421,3491,2511,2991,3851,3481,2911,2181,02971135333915513111498101106111111212991111716678101318273748647588103119134168168185196209227246261258269200200200200200200200100100100100100100100001001001001001001001001001001001000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
984
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,977
12,977
12,977
10,672
10,672
10,672
10,672
10,672
10,672
10,672
10,672
10,672
10,672
10,672
10,672
10,672
10,672
10,672
10,672
10,672
10,672
10,672
10,672
10,67210,67210,67210,67210,67210,67210,67210,67210,67210,67210,67210,67210,67210,67210,67210,67210,67210,67210,67210,67212,97712,97712,97700000000000000000000000000000000098400000000000000000000000000000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,671
4,436
4,338
3,482
0
0
0
0
0
0
0
108,206
55,837
57,963
59,399
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000059,39957,96355,837108,20600000003,4824,3384,4364,67100000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
821
0
0
0
0
0
0
12,604
11,224
15,387
21,850
21,645
20,076
18,620
18,084
21,653
21,090
20,487
19,844
19,202
18,559
46,208
44,840
43,472
42,104
38,848
37,534
36,220
34,906
33,592
32,278
11,491
10,848
10,206
8,646
8,064
7,482
6,900
6,317
5,735
3,600
3,125
49,829
49,321
48,746
48,248
47,750
47,417
47,167
47,032
46,919
46,887
46,854
46,822
46,789
46,757
46,724
46,692
46,659
46,627
46,594
46,562
46,540
46,540
46,540
46,54046,54046,54046,56246,59446,62746,65946,69246,72446,75746,78946,82246,85446,88746,91947,03247,16747,41747,75048,24848,74649,32149,8293,1253,6005,7356,3176,9007,4828,0648,64610,20610,84811,49132,27833,59234,90636,22037,53438,84842,10443,47244,84046,20818,55919,20219,84420,48721,09021,65318,08418,62020,07621,64521,85015,38711,22412,604000000821000000000000000000000000000000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
-100
-100
0
-100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22,248
22,609
890
23,675
826
864
637
649
666
616
601
610
614
630
639
598
591
627
0
588
0
0
0
0
0
00000588062759159863963061461060161666664963786482623,67589022,60922,2480000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000-1000-100-10000000
> Total Liabilities 
300
200
100
100
100
100
100
100
100
100
100
100
100
400
100
0
0
200
100
300
100
1,800
1,600
1,000
800
600
500
400
400
300
500
596
127
308
114
360
136
831
3,452
2,040
2,040
2,284
2,320
2,667
3,188
3,003
3,126
3,502
579
827
756
1,177
1,154
1,470
1,683
2,155
2,155
2,365
2,400
2,516
2,516
2,837
2,906
3,221
3,221
4,530
5,847
5,382
6,636
6,611
5,120
2,386
2,285
2,504
2,385
3,847
4,085
4,588
3,959
4,372
3,147
4,087
3,659
5,454
5,315
5,376
5,485
15,467
12,586
19,401
16,700
12,178
12,192
14,659
15,925
18,213
20,522
10,275
11,333
12,064
15,519
15,168
12,880
8,978
7,940
7,500
6,519
9,414
22,479
19,932
17,459
14,231
14,124
14,387
12,906
12,822
11,358
11,153
11,623
83,647
59,302
54,423
53,595
51,728
44,190
40,430
39,493
38,996
37,493
35,927
31,800
31,80035,92737,49338,99639,49340,43044,19051,72853,59554,42359,30283,64711,62311,15311,35812,82212,90614,38714,12414,23117,45919,93222,4799,4146,5197,5007,9408,97812,88015,16815,51912,06411,33310,27520,52218,21315,92514,65912,19212,17816,70019,40112,58615,4675,4855,3765,3155,4543,6594,0873,1474,3723,9594,5884,0853,8472,3852,5042,2852,3865,1206,6116,6365,3825,8474,5303,2213,2212,9062,8372,5162,5162,4002,3652,1552,1551,6831,4701,1541,1777568275793,5023,1263,0033,1882,6672,3202,2842,0402,0403,4528311363601143081275965003004004005006008001,0001,6001,80010030010020000100400100100100100100100100100100100100200300
   > Total Current Liabilities 
200
200
100
100
0
0
0
100
100
0
100
100
100
300
100
0
0
100
200
300
100
1,300
1,200
800
800
600
400
400
300
300
500
596
127
308
114
360
136
831
3,452
309
309
356
278
498
429
317
2,704
3,094
185
148
131
275
268
267
235
707
707
461
498
616
616
929
991
1,458
1,458
2,840
3,965
3,379
4,484
4,250
1,137
1,162
1,127
1,382
1,299
2,480
2,727
3,287
2,722
3,147
1,966
2,962
2,573
4,391
4,295
4,435
4,598
6,958
5,621
5,069
5,789
7,129
8,203
9,192
10,336
12,462
13,669
7,403
8,338
8,850
8,820
13,530
6,012
6,879
5,810
5,843
4,503
6,812
8,723
7,859
6,162
6,494
6,969
7,519
7,751
7,769
6,621
6,768
8,791
47,116
24,593
25,091
22,739
18,981
17,225
16,052
15,881
17,960
16,890
15,275
13,864
13,86415,27516,89017,96015,88116,05217,22518,98122,73925,09124,59347,1168,7916,7686,6217,7697,7517,5196,9696,4946,1627,8598,7236,8124,5035,8435,8106,8796,01213,5308,8208,8508,3387,40313,66912,46210,3369,1928,2037,1295,7895,0695,6216,9584,5984,4354,2954,3912,5732,9621,9663,1472,7223,2872,7272,4801,2991,3821,1271,1621,1374,2504,4843,3793,9652,8401,4581,4589919296166164984617077072352672682751311481853,0942,7043174294982783563093093,4528311363601143081275965003003004004006008008001,2001,300100300200100001003001001001000100100000100100200200
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
3,350
0
0
0
0
0
0
0
2,454
2,685
2,685
0
0
0
0
0
0
0
567
279
315
0
100
306
354
717
717
1,924
2,691
1,886
3,519
3,314
135
0
0
0
0
0
0
0
0
0
0
0
0
2,822
0
0
0
0
0
58
61
118
227
296
396
133
117
268
625
1,134
1,194
2,679
139
364
342
345
301
307
972
956
1,138
1,223
1,240
1,764
1,011
1,285
1,309
807
818
831
750
622
568
952
963
987
936
1,764
1,101
2,230
1,137
1,1372,2301,1011,7649369879639525686227508318188071,3091,2851,0111,7641,2401,2231,1389569723073013453423641392,6791,1941,1346252681171333962962271186158000002,8220000000000001353,3143,5191,8862,6911,924717717354306100031527956700000002,6852,6852,45400000003,3505000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
70
70
18
0
0
0
0
523
523
523
523
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000052352352352300001870700000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
200
200
100
100
0
0
0
100
100
0
100
100
100
300
100
0
0
100
200
300
100
200
200
300
300
200
100
0
300
300
500
596
127
308
114
360
136
331
102
0
309
356
278
358
429
317
250
409
185
148
131
275
268
267
235
0
567
279
315
0
432
433
442
0
480
623
959
0
0
0
0
0
0
0
0
0
0
1,467
983
0
602
891
709
3,990
1,461
1,688
2,202
3,888
2,527
1,880
2,423
6,803
2,707
2,661
1,934
2,798
4,546
1,758
7,176
7,144
1,064
5,130
508
938
703
1,181
717
6,463
1,379
2,778
2,009
5,226
5,321
3,424
3,155
2,611
2,797
2,720
3,457
3,543
2,956
2,589
2,865
2,393
3,001
2,187
2,430
2,050
2,211
2,388
1,599
1,5992,3882,2112,0502,4302,1873,0012,3932,8652,5892,9563,5433,4572,7202,7972,6113,1553,4245,3215,2262,0092,7781,3796,4637171,1817039385085,1301,0647,1447,1761,7584,5462,7981,9342,6612,7076,8032,4231,8802,5273,8882,2021,6881,4613,99070989160209831,467000000000095962348004424334320315279567023526726827513114818540925031742935827835630901023311363601143081275965003003000100200300300200200100300200100001003001001001000100100000100100200200
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,100
1,000
500
500
400
300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
140
-450
-436
-422
-408
-394
-680
-625
-902
0
-553
-529
0
567
279
315
0
0
0
1
0
0
0
-1,261
1,180
651
629
709
794
503
796
712
1,930
2,244
1,313
1,269
2,681
900
1,595
1,453
2,822
2,440
2,285
1,999
2,835
2,916
2,862
3,127
4,507
3,615
3,943
5,859
6,579
6,128
4,750
5,489
5,551
5,883
5,100
4,852
4,780
4,000
3,847
3,365
4,104
6,329
4,081
2,833
2,799
1,802
2,034
3,539
3,680
2,414
2,628
3,541
24,623
6,002
6,095
6,942
6,215
2,252
2,499
2,600
3,338
3,472
1,515
2,878
2,8781,5153,4723,3382,6002,4992,2526,2156,9426,0956,00224,6233,5412,6282,4143,6803,5392,0341,8022,7992,8334,0816,3294,1043,3653,8474,0004,7804,8525,1005,8835,5515,4894,7506,1286,5795,8593,9433,6154,5073,1272,8622,9162,8351,9992,2852,4402,8221,4531,5959002,6811,2691,3132,2441,9307127965037947096296511,180-1,26100010003152795670-529-5530-902-625-680-394-408-422-436-45014000000000000000003004005005001,0001,100000000000000000000000
   > Long-term Liabilities 
100
200
100
100
100
100
100
100
100
100
100
100
100
100
100
0
0
100
-100
300
100
500
400
200
300
200
100
0
100
300
500
596
127
308
114
360
136
831
3,400
1,731
1,731
1,928
2,042
2,169
2,759
2,686
422
408
394
680
625
902
886
1,203
1,448
0
1,449
1,904
1,902
0
1,900
1,908
1,915
0
1,763
1,690
1,882
2,004
2,152
2,362
3,982
1,224
1,158
1,122
1,085
1,367
1,358
1,301
1,237
1,225
1,181
1,125
1,086
1,063
1,019
941
887
8,510
6,965
14,332
10,911
5,049
3,989
5,467
5,589
5,751
6,853
2,872
2,995
3,214
6,699
1,638
6,868
2,099
2,130
1,657
2,016
2,602
13,756
12,073
11,297
7,737
7,155
6,868
5,155
5,053
4,737
4,385
2,832
36,531
34,709
29,332
30,856
32,747
26,965
24,378
23,612
21,036
20,603
20,652
17,936
17,93620,65220,60321,03623,61224,37826,96532,74730,85629,33234,70936,5312,8324,3854,7375,0535,1556,8687,1557,73711,29712,07313,7562,6022,0161,6572,1302,0996,8681,6386,6993,2142,9952,8726,8535,7515,5895,4673,9895,04910,91114,3326,9658,5108879411,0191,0631,0861,1251,1811,2251,2371,3011,3581,3671,0851,1221,1581,2243,9822,3622,1522,0041,8821,6901,76301,9151,9081,90001,9021,9041,44901,4481,2038869026256803944084222,6862,7592,1692,0421,9281,7311,7313,4008311363601143081275965003001000100200300200400500100300-10010000100100100100100100100100100100100100100200100
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
58
45
409
578
3,334
4,357
4,970
6,054
996
1,216
0
0
0
0
0
0
0
0
1,958
103
93
87
77
66
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000667787931031,958000000001,2169966,0544,9704,3573,334578409455800000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
685
644
9,637
8,155
7,123
3,792
3,562
3,530
3,326
2,513
2,494
2,291
933
34,560
32,902
27,854
28,624
29,803
0
21,961
0
0
0
0
0
0000021,961029,80328,62427,85432,90234,5609332,2912,4942,5133,3263,5303,5623,7927,1238,1559,6376446850000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,314
6,957
14,264
10,787
4,612
3,373
2,103
1,214
773
799
462
385
0
0
0
0
0
0
0
0
0
0
7,534
0
3,515
3,315
3,315
3,137
2,076
2,076
1,907
894
34,530
32,897
27,850
28,620
29,801
24,290
21,961
0
0
0
0
0
0000021,96124,29029,80128,62027,85032,89734,5308941,9072,0762,0763,1373,3153,3153,51507,53400000000003854627997731,2142,1033,3734,61210,78714,2646,9578,314000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
4,900
4,600
4,400
4,000
3,800
3,400
3,400
2,700
6,300
5,800
5,400
4,600
4,000
3,200
2,900
0
0
2,800
2,400
2,000
7,600
6,500
6,100
5,700
4,800
4,000
3,300
0
8,900
8,100
6,500
5,083
3,924
2,501
2,200
1,318
754
-170
-1,068
0
-99
-1,553
-357
-1,171
-1,767
-2,196
-1,826
-2,431
1,702
1,333
880
345
-321
-740
-1,114
0
-197
-1,225
-1,557
0
-1,865
-2,637
-2,844
0
-3,046
-3,921
-4,821
-4,347
-4,940
-828
4,146
7,046
6,441
27,761
35,157
38,172
40,857
36,144
33,625
28,646
24,199
23,177
16,940
9,585
15,845
20,916
12,940
14,801
19,243
17,912
10,981
36,456
26,250
16,979
13,043
26,891
10,852
85,743
119,391
117,928
187,372
176,125
198,286
162,641
99,968
100,981
171,127
93,840
162,844
133,387
117,157
112,959
106,499
99,442
91,266
96,199
117,674
124,713
120,712
92,221
86,547
82,847
78,948
73,339
70,450
72,667
68,117
63,419
72,402
68,300
64,794
64,79468,30072,40263,41968,11772,66770,45073,33978,94882,84786,54792,221120,712124,713117,67496,19991,26699,442106,499112,959117,157133,387162,84493,840171,127100,98199,968162,641198,286176,125187,372117,928119,39185,74310,85226,89113,04316,97926,25036,45610,98117,91219,24314,80112,94020,91615,8459,58516,94023,17724,19928,64633,62536,14440,85738,17235,15727,7616,4417,0464,146-828-4,940-4,347-4,821-3,921-3,0460-2,844-2,637-1,8650-1,557-1,225-1970-1,114-740-3213458801,3331,702-2,431-1,826-2,196-1,767-1,171-357-1,553-990-1,068-1707541,3182,2002,5013,9245,0836,5008,1008,90003,3004,0004,8005,7006,1006,5007,6002,0002,4002,800002,9003,2004,0004,6005,4005,8006,3002,7003,4003,4003,8004,0004,4004,6004,900
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,500
27,100
27,200
27,361
27,267
28,192
28,360
28,748
28,944
28,949
0
30,602
30,637
32,412
32,375
32,530
32,856
32,864
32,858
38,633
38,706
38,706
38,718
38,779
38,802
38,844
0
40,251
40,369
40,377
0
40,494
40,574
40,579
0
40,704
40,968
41,146
43,185
44,110
49,693
58,243
59,722
60,403
83,989
96,050,102
101,135
107,852
108,348
114,740
115,145
115,548
120,163
120,906
119,821
135,595
148,003
149,008
203,456
211,943
199,944
201,298
234,843
234,752
235,555
248,069
274,342
275,238
310,881
313,506
317,878
333,997
334,538
342,508
378,487
379,186
383,529
386,858
354,270
384,553
385,615
386,454
387,062
387,686
388,271
388,190
393,944
415,259
428,046
432,250
434,529
435,818
437,151
439,148
440,280
441,299
448,249
450,282
451,343
466,571
467,928
469,268
469,268467,928466,571451,343450,282448,249441,299440,280439,148437,151435,818434,529432,250428,046415,259393,944388,190388,271387,686387,062386,454385,615384,553354,270386,858383,529379,186378,487342,508334,538333,997317,878313,506310,881275,238274,342248,069235,555234,752234,843201,298199,944211,943203,456149,008148,003135,595119,821120,906120,163115,548115,145114,740108,348107,852101,13596,050,10283,98960,40359,72258,24349,69344,11043,18541,14640,96840,704040,57940,57440,494040,37740,36940,251038,84438,80238,77938,71838,70638,70638,63332,85832,86432,85632,53032,37532,41230,63730,602028,94928,94428,74828,36028,19227,26727,36127,20027,10026,50000000000000000000000000000000
   Retained Earnings -400,192-397,158-391,398-384,856-380,081-372,971-367,742-363,370-357,016-350,947-344,184-337,097-308,105-300,282-295,494-294,078-296,103-288,343-281,821-273,422-268,940-252,435-222,403-261,856-216,905-283,630-279,416-216,297-144,363-158,684-147,033-196,321-190,534-221,743-246,293-229,181-215,757-202,055-192,358-182,190-171,607-163,387-153,878-145,779-126,166-117,178-109,615-101,896-95,861-90,899-85,443-80,470-75,109-71,597-67,317-63,955-60,985-56,316-54,057-52,770-54,190-50,615-49,144-47,625-46,060-44,983-43,844-43,844-43,518-43,304-42,406-42,406-42,028-41,688-40,542-40,542-40,052-39,637-39,194-38,467-37,919-37,467-37,025-35,382-34,784-35,146-34,391-33,640-32,864-32,285-30,795-30,795-30,111-29,208-28,088-27,136-26,086-24,861-23,531-22,211-20,800-18,500-17,500-16,700-15,800-14,600-13,900-12,800-12,200-11,200-10,100-9,600-8,800-8,10000-6,500-6,100-5,400-4,900-4,200-3,700-3,300-2,900-2,200-2,200-1,900-1,600-1,300-1,000-700
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
94
94
60
60
7
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000007760609494000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000-2,891-2,891-18,033-18,033-19,182-19,890-19,890-19,890-22,119-22,119-42,373-43,034000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
5,600
5,600
5,700
5,600
5,700
5,600
5,600
5,600
9,600
9,500
9,600
9,500
9,500
9,400
9,500
0
0
11,000
11,300
11,700
17,800
17,800
18,300
18,500
18,700
18,600
19,100
0
26,600
300
500
371
389
407
427
446
466
482
490
0
503
537
553
572
587
600
611
627
638
648
657
663
663
667
668
0
669
41,043
41,051
0
41,122
41,252
41,258
0
41,384
41,651
41,834
43,881
705
713
720
59,871
60,562
84,083
96,144
101,229
107,946
108,442
108,834
109,239
109,642
114,257
112,998
-8,281
-10,224
-10,027
-10,027
-42,940
-42,279
-22,060
-22,060
-19,883
-19,883
-19,890
-19,182
-18,033
-18,033
-2,891
-2,891
-2,891
2,325
2,060
10,701
2,073
2,487
3,770
1,174
1,426
694
207
-357
-681
634
-486
-821
-3,667
-2,091
-3,051
431,127
433,206
-5,087
-3,357
-3,184
-3,571
-1,435
-2,611
-1,457
-1,396
-1,412
0
-1,392
-1,3920-1,412-1,396-1,457-2,611-1,435-3,571-3,184-3,357-5,087433,206431,127-3,051-2,091-3,667-821-486634-681-3572076941,4261,1743,7702,4872,07310,7012,0602,325-2,891-2,891-2,891-18,033-18,033-19,182-19,890-19,883-19,883-22,060-22,060-42,279-42,940-10,027-10,027-10,224-8,281112,998114,257109,642109,239108,834108,442107,946101,22996,14484,08360,56259,87172071370543,88141,83441,65141,384041,25841,25241,122041,05141,0436690668667663663657648638627611600587572553537503049048246644642740738937150030026,600019,10018,60018,70018,50018,30017,80017,80011,70011,30011,000009,5009,4009,5009,5009,6009,5009,6005,6005,6005,6005,7005,6005,7005,6005,600



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue8,945
Cost of Revenue-671
Gross Profit8,2748,274
 
Operating Income (+$)
Gross Profit8,274
Operating Expense-33,007
Operating Income-24,733-24,733
 
Operating Expense (+$)
Research Development15,705
Selling General Administrative17,302
Selling And Marketing Expenses562
Operating Expense33,00733,569
 
Net Interest Income (+$)
Interest Income1,629
Interest Expense-0
Other Finance Cost-0
Net Interest Income1,629
 
Pretax Income (+$)
Operating Income-24,733
Net Interest Income1,629
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-23,282-26,184
EBIT - interestExpense = -24,733
-23,289
-21,486
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-24,733-23,282
Earnings Before Interest and Taxes (EBITDA)-24,041
 
After tax Income (+$)
Income Before Tax-23,282
Tax Provision--1,803
Net Income From Continuing Ops-21,479-21,479
Net Income-21,486
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses33,678
Total Other Income/Expenses Net1,451-1,629
 

Technical Analysis of Lineage Cell Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lineage Cell Therapeutics Inc. The general trend of Lineage Cell Therapeutics Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lineage Cell Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Lineage Cell Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.52 < 0.62 < 0.7665.

The bearish price targets are: .

Tweet this
Lineage Cell Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Lineage Cell Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Lineage Cell Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Lineage Cell Therapeutics Inc. The current macd is -0.06438353.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Lineage Cell Therapeutics Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Lineage Cell Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Lineage Cell Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Lineage Cell Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartLineage Cell Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Lineage Cell Therapeutics Inc. The current adx is 39.08.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Lineage Cell Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Lineage Cell Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Lineage Cell Therapeutics Inc. The current sar is 0.5682.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Lineage Cell Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Lineage Cell Therapeutics Inc. The current rsi is 42.61. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Lineage Cell Therapeutics Inc Daily Relative Strength Index (RSI) ChartLineage Cell Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Lineage Cell Therapeutics Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Lineage Cell Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Lineage Cell Therapeutics Inc Daily Stochastic Oscillator ChartLineage Cell Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Lineage Cell Therapeutics Inc. The current cci is -32.53236619.

Lineage Cell Therapeutics Inc Daily Commodity Channel Index (CCI) ChartLineage Cell Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Lineage Cell Therapeutics Inc. The current cmo is -4.44812781.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Lineage Cell Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartLineage Cell Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Lineage Cell Therapeutics Inc. The current willr is -44.60431655.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Lineage Cell Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Lineage Cell Therapeutics Inc Daily Williams %R ChartLineage Cell Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Lineage Cell Therapeutics Inc. The current atr is 0.05848878.

Lineage Cell Therapeutics Inc Daily Average True Range (ATR) ChartLineage Cell Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Lineage Cell Therapeutics Inc. The current obv is -44,907,426.

Lineage Cell Therapeutics Inc Daily On-Balance Volume (OBV) ChartLineage Cell Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Lineage Cell Therapeutics Inc. The current mfi is 32.98.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Lineage Cell Therapeutics Inc Daily Money Flow Index (MFI) ChartLineage Cell Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Lineage Cell Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-08-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-07STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-14STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-15MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-10BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-10-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-11BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-22ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-12-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-12-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Lineage Cell Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Lineage Cell Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.607
Ma 20Greater thanMa 500.552
Ma 50Greater thanMa 1000.736
Ma 100Greater thanMa 2000.813
OpenGreater thanClose0.520
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Lineage Cell Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Lineage Cell Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lineage Cell Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Lineage Cell Therapeutics Inc

I send you an email if I find something interesting about Lineage Cell Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Lineage Cell Therapeutics Inc.

Receive notifications about Lineage Cell Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.